

## 세포교정영양요법(OCNT)을 이용한 유방암 환자 사례 연구

장지연 약사

서울광역시 은평구 응암로 22길 22, 이화약국

## A Case Study on the Breast Cancer Patients Using Ortho-Cellular Nutrition Therapy (OCNT)

Pharmacist, Jang Ji-Youn

Ewha Pharmacy, 22, Eungam-ro 22-gil, Eunpyeong-gu, Seoul, Republic of Korea

## ABSTRACT

**Objective:** Case report of improvement in joint pain and gum bleeding in a breast cancer patient using OCNT.

**Methods:** A Korean woman in her 60s was diagnosed with breast cancer. After being diagnosed with stage 2 breast cancer, her quality of life has greatly deteriorated due to the side effects of the drugs administered.

**Results:** Improved joint pain and bleeding gums after OCNT

**Conclusion:** The application of OCNT to patients with above problem can help improve symptoms.

**Keywords:** Ortho-Cellular Nutrition Therapy (OCNT), breast cancer, improved adverse drug reaction, arthralgia, gum bleeding

## Introduction

Breast cancer refers to any malignant tumor that develops in the lactiferous duct and lobules of the breast, and is a deadly disease in which abnormal tissue in the breast continues to grow or spreads to other organs. Breast tissue is made up of the mammary glands and the

fat, connective tissue, and lymphatic vessels that support breast tissue. Breast cancer is more diverse than other cancers because it can occur anywhere in the breast tissue.<sup>1,2</sup>

According to the International Cancer Report 2020, breast cancer is known to be more prevalent in countries with higher income levels. Thus, South Korea has a high incidence of breast cancer.<sup>1,3</sup>

Of these, 70% are affected by hormones such as estrogen and progesterone and are referred to as hormone-positive breast cancer patients.<sup>4</sup> Patients with hormone-driven disease are prescribed hormone inhibitors for 5-10 years after diagnosis, which block the production of female sex hormones (aromatase

\*Correspondence: Ji Yeon Jang

E-mail: comus104@hanmail.net

Received Jul 27, 2023; Accepted Jul 28, 2023; Published Jul 31, 2023

doi: <http://dx.doi.org/10.5667/CellMed.spc.037>

©2023 by CellMed Orthocellular Medicine Pharmaceutical Association

This is an open access article under the CC BY-NC license.

<http://creativecommons.org/licenses/by-nc/3.0/>

† This report has been translated and edited by the CellMed editor-in-chief, Prof. Beom-Jin Lee.

inhibitors, luteinizing hormone-releasing hormone analogs) or inhibit their action (selective estrogen receptor modulators). Antihormonal therapy is considered the first-line treatment for hormone receptor-positive breast cancer because it can effectively treat breast cancer with fewer side effects than chemotherapeutic agents.<sup>4,5</sup>

Tamoxifen, the most widely used anti-estrogenic breast cancer drug, has been shown to be effective in preventing recurrent metastases.<sup>5</sup>

In fact, an NSABP-14 study conducted on 2,644 patients (a randomized, double-blind, placebo-controlled trial) showed that taking tamoxifen reduces recurrence and mortality in patients with early-stage breast cancer without lymph node metastases, compared to a 15-year recurrence rate of 46.3% without tamoxifen, the intake reduced it to 33.7%.<sup>6</sup>

Tamoxifen's shows pharmacologic activity dependent on conversion by CYP2D6 to its active metabolite, endoxifen. When tamoxifen is administered, it intentionally competes with estrogen to bind to the ER and replaces estrogen. Tamoxifen may also bind to calmodulin, a calcium-modulated protein that affects DNA synthesis and thus inhibits cell proliferation.<sup>7</sup>

With this pharmacologic mechanism, tamoxifen acts as a competitive substrate inhibitor of estrogen and may cause estrogen deficiency as a side effect. These side effects are very similar to menopausal symptoms in women.<sup>7,8</sup>

The most common symptoms are irregular menstrual patterns, hot flashes on the face and upper body, heart palpitations, dry vulva, painful urination, and osteoporosis, which can lead to arthritis and joint pain.<sup>8</sup>

Because of these side effects, 83% of patients prescribed tamoxifen in the first year took their prescribed medication, but after four years, only 50% took their medication. Globally, tamoxifen has a patient-led drug discontinuation rate of about 30-40%, meaning

that people receive a prescription for the drug but discard it without taking it.<sup>9</sup>

If a patient stops taking the drug because of side effects, even if the treatment is highly effective, this can lead to another cancer recurrence.

In this case, the patient was diagnosed with stage 2 hormone-positive breast cancer (June 2015) and had been taking Femara (Retrozol) for over 4 years after taking Tamoxifen for 2 years. Femara is an aromatase inhibitor that is prescribed to postmenopausal hormone-positive breast cancer patients, which is known to increase the risk of osteoporosis.<sup>10</sup>

In this case, the patient complained of joint pain due to long-term antihormonal medication, and OCNT was implemented to reduce the pain and improve joint recovery, and we would like to report the results.

## Cases

### 1. Target

It targeted one patient with breast cancer.

- 1) Name: Yoo, O O (F/60 years old)
- 2) Diagnosis: Breast cancer
- 3) Date of Onset: June 2015
- 4) Treatment Period: March 2022 to September 2022 (Approximately 9 months)
- 5) Chief Complaint: Arthralgia
- 6) Past History: Breast cancer
- 7) Social History: None
- 8) Family History: None
- 9) Current Medical History: None

### 2. Method

To alleviate arthralgia,

Sulfoplex PK (333, three times a day, 3 tablets per dose)

Collaplex (101, twice a day, one sachet per dose)

were administered as an initial OCNT. The patient stopped taking Femara after noticing that the side effects of joint pain and bleeding gums were disappearing.

Cyaplex (101, twice a day, one sachet per dose)

Eufaplex (101, twice a day, one sachet per dose)

Tmplex (200, once a day, 2 sachets per dose)

Sulfoplex (303, twice a day, 3 tablets per dose)

Thyroplex (101, twice a day, one sachet per dose)

were administered. After the patient stopped taking female hormone inhibitors due to discontinuation of Femara and developed insomnia because of anxiety from fear of cancer recurrence, she resumed Femara with 15 days of

Viva C Cap. (101, twice a day, one tablet per dose)

Jubaplex (011, twice a day, one sachet per dose)

administration. After her insomnia improved, she stopped taking Femara. Simultaneously, to alleviate the iodine and vitamin D deficiencies seen in breast cancer patients,

Cyaplex (101, twice a day, one sachet per dose)

Eufaplex (101, twice a day, one sachet per dose)

Tmplex (100, once a day, one sachet per dose)

Sulfoplex (303, twice a day, 3 tablets per dose)

Thyroplex (101, twice a day, one sachet per dose)

Diverol Cap. (101, twice a day, one capsule per dose)

were administered.

After 3 months of maintenance, Diverol capsules were added, and the pain significantly improved. Afterward,

**Table 1. The indicator for the chief complaint was filled out by the patient herself.** The level of intensity worsens from 1 to it reaches 10.

Symptoms	1st Mar. 2023	2nd Apr. 2022	3rd May 2022	4th Jun. 2022	5th Jul. 2022 or later	Remarks
Arthralgia (Waist)	8	1	0	0	0	
Arthralgia (Sholder)	7	2	1	0	0	
Gum bleeding		5	1	0	0	
Insomnia				7	0	

the dose of Sulfoplex (202, twice a day, 2 sachets per dose)

was reduced and continued for 2 more months.

### Result

After the first round of OCNT, there was a significant improvement in arthritis compared to before. Arthralgia, especially in the back and shoulders, decreased significantly after about three months of taking the supplement, and additional symptoms such as bleeding gums and insomnia also improved significantly (**Table. 1**).

### Consideration

In this case, the patient developed arthralgia due to medication for breast cancer treatment, and OCNT therapy was performed to alleviate it.

To relieve arthralgia, we prescribed Sulfoplex PK tablets, which contain MSM, peony, licorice, hyssop, etc. to strengthen joints and magnesium glycine to stabilize nerves. We expected the formula to have effect on arthralgia.

Paeoniflorin and albiflorin, substances found in *Paeonia radix*, are known to improve rheumatoid arthritis, etc. They inhibit the TRPV1 and Succinate/SUCNR1-HIF-1a/NLPR3 pathways to reduce

pain, or inhibit the NF- $\kappa$ B signaling pathway in osteoclast differentiation to reduce collagen-induced arthritis or arthralgia.<sup>11, 12</sup>

Hyssop (*Achyranthes japonica*) is also known to be effective for arthralgia, especially by inhibiting matrix metalloproteinases (MMP), which have been linked to osteoporosis. In particular, the level of MMP-2, which breaks down collagen, and MMP-9, an important factor in the breakdown of collagen, gelatin, proteoglycans, and elastin, were found to be lower in hyssop-treated patients compared to controls.<sup>13</sup> These effects may help stabilize bone density, which in turn improves pain and inflammation in the joint. Since the drugs tamoxifen and Femara, which are used to treat breast cancer, have the side effect of osteoporosis, we believe that implementing OCNT will actually help improve arthralgia.

Besides, combination therapies such as Collaplex, which contains collagen, and Cyaplex, which contains anthocyanin extracted from aronia, were used to improve the side effects of breast cancer, as well as to improve actual cancer tissues through antioxidant effects, etc.

The Aronia extract exhibits antioxidant properties in plasma and platelets in healthy individuals as well as breast cancer patients, and when given to patients undergoing breast cancer treatment or post-operative chemotherapy, it has been shown to significantly reduce oxidative/nitrosative stress in platelets of breast cancer patients.<sup>13</sup>

Thus, it is conceivable that the OCNT currently being implemented may provide a pharmacologic mechanism to help improve the side effects of breast cancer medications as well as the disease itself.

However, since it is a single case and there are limitations in interpreting the results, it is difficult to apply it to all patients. However, it is thought to be a case that helped improve arthralgia symptoms by adjusting the appropriate concentration of OCNT according to the patient's condition and is reported with the patient's

consent.

## References

- 1 International Agency for Research on Cancer publication. <https://publications.iarc.fr/Non-series-Publications/World-Cancer-Reports/World-Cancer-Report-Cancer-Research-For-Cancer-Prevention-2020>.
- 2 Sharma, Ganesh N, *et al.* "Various types and management of breast cancer: an overview." *Journal of advanced pharmaceutical technology & research* **1** (2),109 (2010).
- 3 Suh, Mina, *et al.* "Trends in cancer screening rates among Korean men and women: results of the Korean National Cancer Screening Survey, 2004-2013." *Cancer research and treatment: official journal of Korean Cancer Association* **48**, 1, 1-10 (2016).
- 4 Stalsberg, Helge, *et al.* "Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men." *Cancer causes & control* **4** , 143-151 (1993).
- 5 Viedma-Rodríguez, Rubí, *et al.* "Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer." *Oncology reports* **32.1**, 3-15 (2014)
- 6 Ahmed, Muneer, and Michael Douek. "The management of screen-detected breast cancer." *Anticancer research* **34.3**, 1141-1146 (2014).
- 7 Yang, Geniey, *et al.* "Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs." *Pharmacology & therapeutics* **139.3**, 392-404 (2013).
- 8 Riggs, B. Lawrence, and Lynn C. Hartmann. "Selective estrogen-receptor modulators—

mechanisms of action and application to clinical practice." *New England Journal of Medicine* **348.7**, 618-629 (2003).

- 9 Partridge, Ann H., et al. "Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer." *Journal of Clinical Oncology* **21.4**, 602-606 (2003).
- 10 Garreau, Jennifer R., et al. "Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective." *The American journal of surgery* **192.4**: 496-498 (2006).
- 11 Xu, Haiyan, et al. "Paeoniflorin ameliorates collagen-induced arthritis via suppressing nuclear factor- $\kappa$ B signalling pathway in osteoclast differentiation." *Immunology* **154.4**: 593-603 (2018).
- 12 Ruan, Yonglan, et al. "Paeoniflorin alleviates CFA-induced inflammatory pain by inhibiting TRPV1 and succinate/SUCNR1-HIF-1 $\alpha$ /NLPR3 pathway." *International Immunopharmacology* **101**, 108364 (2021).
- 13 Kang, Hyo Seok, et al. "Effect of fermented *Achyranthes japonica* (Miq.) Nakai extract on osteoarthritis." *Korean Journal of Food Science and Technology* **49.1**, 104-109 (2017).
- 13 Kedzierska, Magdalena, et al. "Effects of the commercial extract of aronia on oxidative stress in blood platelets isolated from breast cancer patients after the surgery and various phases of the chemotherapy." *Fitoterapia* **83.2**, 310-317 (2012).